Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O14815
UPID:
CAN9_HUMAN
Alternative names:
Digestive tract-specific calpain; New calpain 4; Protein CG36
Alternative UPACC:
O14815; B1APS1; B1AQI0; Q9NS74
Background:
Calpain-9, identified by its UniProt accession number O14815, is known by several alternative names including Digestive tract-specific calpain, New calpain 4, and Protein CG36. This protein functions as a calcium-regulated non-lysosomal thiol-protease, indicating its unique role in calcium-mediated cellular processes.
Therapeutic significance:
Understanding the role of Calpain-9 could open doors to potential therapeutic strategies. Its unique calcium-regulated activity suggests a pivotal role in cellular functions, which, when elucidated, could offer novel therapeutic avenues.